1.1600 +0.08 (7.41%)
Pre-Market: 4:24AM EDT
Previous Close | 1.1200 |
Open | 1.1300 |
Bid | 0.0000 x 3200 |
Ask | 0.0000 x 900 |
Day's Range | 1.0700 - 1.1599 |
52 Week Range | 1.0700 - 2.5800 |
Volume | 215,260 |
Avg. Volume | 433,353 |
Market Cap | 62.291M |
Beta (5Y Monthly) | 2.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2400 |
Earnings Date | Nov 05, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.33 |
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2020 and announced recent business highlights.
NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Stealth BioTherapeutics Corp. (NASDAQ:MITO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on April 6, 2021 at 8:30 AM Eastern Time.
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens.